XNCR
Xencor Inc
Halal Rating :
Last Price
$19.24
Last updated:
Market Cap
-
7D Change
-5.03%
1 Year Change
-3.9%
Company Overview
Industries
Exchange
Next Earnings Date
Xencor Inc is a clinical-stage biopharmaceutical company that develops engineered monoclonal antibodies and cytokines for the treatment of cancer and autoimmune diseases. The company's XmAb technology platform enables the creation of therapeutic candidates with enhanced properties and functions.
The company focuses on developing treatments in oncology and autoimmune diseases through its proprietary protein engineering capabilities. Their business model primarily revolves around research, development, and potential commercialization of novel therapeutic antibodies.
Use of Interest
| Reporting Date | Total Revenue | Total Operating Expense | Interest Income | Interest Expense | Interest Income Ratio | Interest Expense Ratio |
|---|---|---|---|---|---|---|
| Sept. 30, 2024 | $10.71m | $73.79m | - | $795000.0 | 0.00% | 1.08% |
| June 30, 2024 | $16.96m | $80.12m | - | $844000.0 | 0.00% | 1.05% |
| March 31, 2024 | $12.8m | $63.19m | - | $-7471000.0 | 0.00% | 11.82% |
Company Impact
Help us evaluate Xencor Inc's impact from a halal perspective. Vote on the most significant aspect and submit any considerations that we may have missed.